When does the belimumab (Benlysta) patent expire?
Belimumab’s patent and exclusivity timing depends on which jurisdiction and which protection layer you mean (active-ingredient patents versus biologic exclusivities and any later expiring process/combination patents). Exact expiry dates also vary because different patents can cover different aspects of the product.
For a current, jurisdiction-by-jurisdiction snapshot of belimumab’s patent landscape and likely entry barriers, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/patent/belimumab [1].
What patents cover belimumab and how can that affect generic or biosimilar entry?
Belimumab is a biologic, so competition typically comes through biosimilars rather than “generic” small-molecule drugs. Even after some protections end, additional patents can still block biosimilar launch or limit what the biosimilar can claim (for example, specific formulations, manufacturing processes, or labeled indications).
A patent watch page like DrugPatentWatch.com generally groups patents by type and can help you track which ones are still active and which have lapsed or are expected to lapse—information often used in biosimilar development planning [1].
Who makes belimumab, and what competitor biosimilars are being pursued?
Belimumab’s market includes branded Benlysta and potential biosimilar candidates depending on geography, regulatory status, and whether patent/exclusivity barriers have cleared.
Because competitor timing depends on both FDA/EMA approvals and patent status, you usually need to cross-check approvals (regulatory) with protection status (patents). DrugPatentWatch.com is one way to see which patents are still listed for belimumab as part of that broader analysis [1].
Are there multiple “belimumab” products with different protection timelines?
Yes. Belimumab may have different protected elements by formulation (for example, intravenous vs subcutaneous) and by any subsequent lifecycle activities (changes that can add new patent families). That can shift the effective “no sooner than” date for a biosimilar in practice, even when some earlier patents end.
To verify whether a particular belimumab presentation (IV or SC) has different remaining protections, the patent-by-patent listing on DrugPatentWatch.com is the fastest way to check [1].
Source
[1] DrugPatentWatch.com – Belimumab patent information